Mory Cherif Haidara

Centre National de la Recherche Appliquée au Developpement Rural

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Abdoul Habib Béavogui

Institut de Recherche Agronomique de Guinée

Djénéba Dabitao

Université des Sciences, des Techniques et des Technologies de Bamako

Renée Ridzon

National Institute of Allergy and Infectious Diseases

Seydou Samaké

Université des Sciences, des Techniques et des Technologies de Bamako

Sally Hunsberger

National Institute of Allergy and Infectious Diseases

Alyson Francis

National Institute of Allergy and Infectious Diseases

Kathryn Shaw‐Saliba

National Institute of Allergy and Infectious Diseases

Moctar Tounkara

Université des Sciences, des Techniques et des Technologies de Bamako

Jean-Luc Biampata

National Institute of Biomedical Research

Seydou Doumbia

Université des Sciences, des Techniques et des Technologies de Bamako

Cooperative Institutions

National Institutes of Health

National Institute of Allergy and Infectious Diseases

Frederick National Laboratory for Cancer Research

National Institute of Biomedical Research

Université des Sciences, des Techniques et des Technologies de Bamako

Leidos (United States)

Leidos Biomedical Research Inc. (United States)

National Cancer Institute

University of Bamako

Institut de Recherche Agronomique de Guinée

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Investigating immune amnesia after measles virus infection in two West African countries: A study protocol

medRxiv (Cold Spring Harbor Laboratory) (2024)

Karine Fouth Tchos Renée Ridzon Mory Cherif Haidara Djénéba Dabitao Esther Akpa

“Investigation of Immune Amnesia Following Measles Infection in Select African Regions” (ClinicalTrials.gov Identifier: NCT06153979 ) is a prospective, observational, longitudinal study being conducted in two West African countries, Guinea, and Mali. The overall goal is to investigate the impact of measles virus (MeV) infection on pre-existing immunity, vaccine response, and susceptibility to subsequent illness. A total of 256 children aged 1 to 15 years are being enrolled into one of two study arms: those with acute MeV infection (cases) and without (controls). Acute MeV is confirmed by RT-PCR testing on upper respiratory specimens or IgM detection on blood samples at screening. Blood samples are collected at multiple time points at screening (Day 0), at an optional visit to repeat IgM serology for inconclusive or negative Day 0 results (Day 7-10), and during follow-up visits on Day 14, Week 13, and Week 52. These blood samples will be tested to evaluate both humoral and cellular immune responses to endemic pathogens to measure variations in antibody diversity and antibody secreting cells (ASCs). To explore how recent MeV infection may affect the child’s ability to respond to a controlled immune stimulus, all participants will receive rabies vaccine pre-exposure prophylaxis (PrEP) using Verorab inactivated rabies vaccine. Three doses of 0.5 ml of VERORAB vaccine are administered on Days 0, 7, and 28. Biological samples will be collected after vaccination to assess if the rabies vaccine response differs: 1) between cases and controls, and 2) based on the timing of the rabies vaccination after acute measles infection. In addition, the study team will collect information on healthcare encounters during the year-long follow-up will be collected to determine if there is a difference in the number of encounters by study group. The findings of this study will further the understanding of the MeV immune amnesia phenotype.

Rabies vaccine

10.1101/2024.11.19.24317598

Cite

Citations (0)

Correction: Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE)

PLoS ONE (2024)

Irini Sereti Kathryn Shaw‐Saliba Lori E. Dodd Robin Dewar Sylvain Laverdure

[This corrects the article DOI: 10.1371/journal.pone.0273914.].

10.1371/journal.pone.0314048

Cite

Citations (0)

Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE)

PLoS ONE (2022)

Irini Sereti Kathryn Shaw‐Saliba Lori E. Dodd Robin Dewar Sylvain Laverdure

In response to the COVID-19 pandemic, COVID-19 vaccines have been developed, and the World Health Oraganization (WHO) has granted emergency use listing to multiple vaccines. Studies of vaccine immunogenicity data from implementing COVID-19 vaccines by national immunization programs in single studies spanning multiple countries and continents are limited but critically needed to answer public health questions on vaccines, such as comparing immune responses to different vaccines and among different populations.

Pandemic

Listing (finance)

10.1371/journal.pone.0273914

Cite

Citations (7)

Rodent control to fight Lassa fever: Evaluation and lessons learned from a 4-year study in Upper Guinea

PLoS neglected tropical diseases (2018)

Almudena Marí Sáez Mory Cherif Haidara Amara Camara Fodé Kourouma Mickaël Sage

Lassa fever is a viral haemorrhagic fever caused by an arenavirus. The disease is endemic in West African countries, including Guinea. The rodents Mastomys natalensis and Mastomys erythroleucus have been identified as Lassa virus reservoirs in Guinea. In the absence of a vaccine, rodent control and human behavioural changes are the only options to prevent Lassa fever in highly endemic areas. We performed a 4 year intervention based on chemical rodent control, utilizing anticoagulant rodenticides in 3 villages and evaluating the rodent abundance before and after treatment. Three additional villages were investigated as controls. Analyses to assess the effectiveness of the intervention, bait consumption and rodent dynamics were performed. Anthropological investigations accompanied the intervention to integrate local understandings of human–rodent cohabitation and rodent control intervention. Patterns of bait consumption showed a peak at days 5–7 and no consumption at days 28–30. There was no difference between Bromadiolone and Difenacoum bait consumption. The main rodent species found in the houses was M. natalensis. The abundance of M. natalensis, as measured by the trapping success, varied between 3.6 and 16.7% before treatment and decreased significantly to 1–2% after treatment. Individuals in treated villages welcomed the intervention and trapping because mice are generally regarded as a nuisance. Immediate benefits from controlling rodents included protection of food and belongings. Before the intervention, local awareness of Lassa fever was non-existent. Despite their appreciation for the intervention, local individuals noted its limits and the need for complementary actions. Our results demonstrate that chemical treatment provides an effective tool to control local rodent populations and can serve as part of an effective, holistic approach combining rodent trapping, use of local rodenticides, environmental hygiene, house repairs and rodent-proof storage. These actions should be developed in collaboration with local stakeholders and communities.

Lassa fever

Mastomys

Viral hemorrhagic fever

Lassa virus

Arenavirus

10.1371/journal.pntd.0006829

Cite

Citations (62)

SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali

International Journal of Infectious Diseases (2024)

Sylvain Laverdure Donatien Kazadi Kadidia Kone Viviane Callier Djénéba Dabitao

The InVITE study, starting in August 2021, was designed to examine the immunogenicity of different vaccine regimens in several countries including the Democratic Republic of Congo, Guinea, Liberia, and Mali. Prevaccination baseline samples were used to obtain estimates of previous SARS-CoV-2 infection in the study population.

Seroprevalence

Pandemic

Herd Immunity

10.1016/j.ijid.2024.106985

Cite

Citations (0)

Challenges of conducting an international observational study to assess immunogenicity of multiple COVID-19 vaccines

PLOS Global Public Health (2023)

Ratna Sardana Placide Mbala Kingebeni Wiwit Agung SNC Abdoul Habib Béavogui Jean-Luc Biampata

The International Study on COVID-19 Vaccines to Assess Immunogenicity, Reactogenicity, and Efficacy is an observational study to assess the immunogenicity of COVID-19 vaccines used in Democratic Republic of Congo, Guinea, Indonesia, Liberia, Mali, Mexico, and Mongolia. The study, which has enrolled 5,401 adults, is prospectively following participants for approximately two years. This study is important as it has enrolled participants from resource-limited settings that have largely been excluded from COVID-19 research studies during the pandemic. There are significant challenges to mounting a study during an international health emergency, especially in resource-limited settings. Here we focus on challenges and hurdles encountered during the planning and implementation of the study with regard to study logistics, national vaccine policies, pandemic-induced and supply chain constraints, and cultural beliefs. We also highlight the successful mitigation of these challenges through the team's proactive thinking, collaborative approach, and innovative solutions. This study serves as an example of how established programs in resource-limited settings can be leveraged to contribute to biomedical research during a pandemic response. Lessons learned from this study can be applied to other studies mounted to respond rapidly during a global health crisis and will contribute to capacity for stronger pandemic preparedness in the future when there is a crucial need for urgent response and data collection.

Pandemic

Preparedness

Reactogenicity

10.1371/journal.pgph.0001918

Cite

Citations (0)